GP1BA and B-cell chronic lymphocytic leukemia: That is, while evidence for platelet dysfunction associated with CLL is more limited than is the case for MDS discussed above, and while spontaneous or clinically significant bleeding is not typically reported as being associated with CLL, significantly decreased levels of expression of GPIbα and GPVI, together with mildly reduced platelet count and/or the increased susceptibility to bleeding in the presence of anti-cancer drugs that impact upon key platelet signalling pathways, may ultimately have consequences in terms of monitoring bleeding risk or use of antiplatelet agents.